

## Engagement Report for Clinical Commissioning Policies

<b>Unique Reference Number</b>	A11X05
<b>Policy Title</b>	Riociguat for Pulmonary Arterial Hypertension
<b>Accountable Commissioner</b>	Kathy Blacker
<b>Clinical Reference Group</b>	Pulmonary Hypertension
Which stakeholders were contacted to be involved in policy development?	Pulmonary Hypertension CRG membership and registered stakeholders.
Identify the relevant Royal College or Professional Society to the policy and indicate how they have been involved	All of the key stakeholders listed above were invited to comment.
Which stakeholders have actually been involved?	All of the key stakeholders listed above were invited to comment.
Explain reason if there is any difference from previous question	Not applicable.

**FOR PUBLIC CONSULTATION ONLY**

<p>Identify any particular stakeholder organisations that may be key to the policy development that you have approached that have yet to be engaged. Indicate why?</p>	<p>None</p>
<p>How have the stakeholders been involved? What engagement methods have been used?</p>	<p>The draft policy was circulated to the full membership of the CRG and registered stakeholders for one week for their views, both to establish whether any amendments to the policy are required, and to understand from their perspective what the key questions to ask at consultation might be.</p> <p>Three responses were received from CRG registered stakeholders and none were received from CRG members.</p> <p>Key responses themes as follows:</p> <ul style="list-style-type: none"> <li>(1) Stakeholder suggested updates to the patient pathway.</li> <li>(2) Stakeholder requested to update the initial dose.</li> <li>(3) Stakeholder requested clarifications to the evidence review.</li> <li>(4) Additional stakeholders (Pulmonary Hypertension Association UK) were identified.</li> </ul>
<p>What has happened or changed as a result of their input?</p>	<p>Stakeholders were invited to comment. Updates were made to the policy proposition and evidence review to address stakeholders' comments:</p> <ul style="list-style-type: none"> <li>(1) patient pathway was updated;</li> <li>(2) initial dose was updated to be consistent with EMA license;</li> <li>(3) and evidence review updated.</li> <li>(4) Additional stakeholders will be included in the public consultation.</li> </ul>
<p>How are stakeholders being kept informed of progress with policy development as a result of their input?</p>	<p>This engagement report, along with the policy proposition will be circulated as part of the public consultation. Stakeholders will be notified and invited to comment further.</p>
<p>What level of wider public consultation is recommended by the CRG for the NPOC Board to agree as a result of stakeholder involvement?</p>	<p>Public consultation for a period of 30 days as supported by stakeholders.</p>